Clinical Lung Cancer posted on X:
“A new retrospective study suggests that EGFR exon 19 non-LRE deletions may be linked to poorer outcomes with osimertinib, and rare exon 19 mutations (e.g., L747P, P753L) exhibit variable responses.”
Title: Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants
Authors: Lih-Chyun Chang, Hsiang-Wei Hu, Min-Shu Hsieh, Shang-Gin Wu, Jin-Yuan Shih
Read The Full Article.
More posts featuring NSCLC.